Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036127 · ClinicalTrials.gov registry record · Phase 2
Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00036127 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization.
The verdict
NCT00036127, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
Study to learn if the alternate formulation is effective in agitated schizophrenic patients
Interventions
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036127
The ClinicalTrials.gov registry entry for NCT00036127 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aripiprazole is the first listed.
NCT00036127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036127 about?
NCT00036127 is a clinical study titled "Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders". Study to learn if the alternate formulation is effective in agitated schizophrenic patients
What is the current status of trial NCT00036127?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-04. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00036127?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00036127?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.